Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
Previous Symbol
CUSIPN/A
Phone781-209-6400
Debt
Debt-to-Equity Ratio0.06
Current Ratio18.46
Quick Ratio18.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$8.21 per share
Price / Book2.83
Profitability
EPS (Most Recent Fiscal Year)($2.99)
Net Income$-50,280,000.00
Net MarginsN/A
Return on Equity-35.38%
Return on Assets-31.94%
Miscellaneous
Employees65
Outstanding Shares37,660,000
Market Cap$863.20 million
OptionableOptionable
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced its earnings results on Thursday, November, 8th. The company reported ($0.65) EPS for the quarter, meeting analysts' consensus estimates of ($0.65). View Deciphera Pharmaceuticals' Earnings History.
When is Deciphera Pharmaceuticals' next earnings date?
What price target have analysts set for DCPH?
10 equities research analysts have issued twelve-month price objectives for Deciphera Pharmaceuticals' shares. Their predictions range from $20.00 to $65.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $45.75 in the next twelve months. This suggests a possible upside of 96.9% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.
What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.
What are Wall Street analysts saying about Deciphera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Deciphera Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. " (11/13/2018)
- 2. Cantor Fitzgerald analysts commented, "We are Overweight on DCPH with a 12-month price target of $53 based on lead asset DCC-2618 (in 4L GIST). Compelling safety and clinical activity data were presented at ASCO ‘18, which we view positively when compared to SOC sunitinib in earlier 2L patients. We believe the recent data de-risks the P3 program for 4L pts, reads on the broad potential in GIST & other malignancies, and reinforces our conviction in the platform/clinical strategy. In addition, emerging ‘2618 data in 2L/3L pts suggest superiority to SOC in terms of response rate & durability, a clinical profile that could drive ~$2.7B in peak sales." (10/3/2018)
- 3. Canaccord Genuity analysts commented, "We continue to expect DCC-2618 durability in GIST cohorts will be a key focus for investors. The Phase 1 is assessing DCC-2618 in 3 separate indications, GIST (cohorts for 2L, 4L, and 5L), advanced systemic mastocytosis (aSM), and glioma/ glioblastoma multiforme (GBM). In November, Deciphera initiated pivotal Invictus trial in 4L GIST and plans to start second Ph3 Intrigue 2L GIST trial by year-end. DCC-2618 has US and EU orphan designation." (8/13/2018)
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
Headlines about DCPH stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Are investors shorting Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,843,057 shares, an increase of 58.5% from the October 15th total of 1,162,575 shares. Based on an average trading volume of 401,729 shares, the days-to-cover ratio is currently 4.6 days. Currently, 12.4% of the company's shares are sold short. View Deciphera Pharmaceuticals' Current Options Chain.
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), Mallinckrodt (MNK), Ascendis Pharma A/S (ASND), Myokardia (MYOK), Allakos (ALLK), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), ACADIA Pharmaceuticals (ACAD) and Xencor (XNCR).
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
- Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
- Dr. Stephen B. Ruddy, Chief Technical Officer
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
Who are Deciphera Pharmaceuticals' major shareholders?
Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (2.49%), Emerald Advisers Inc. PA (1.87%), Janus Henderson Group PLC (1.80%), BlackRock Inc. (1.79%), Emerald Mutual Fund Advisers Trust (1.77%) and Alliancebernstein L.P. (1.55%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.
Which institutional investors are selling Deciphera Pharmaceuticals stock?
DCPH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Laurion Capital Management LP, Nexthera Capital LP, Vivo Capital LLC, Russell Investments Group Ltd. and Virtus ETF Advisers LLC. View Insider Buying and Selling for Deciphera Pharmaceuticals.
Which institutional investors are buying Deciphera Pharmaceuticals stock?
DCPH stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Emerald Mutual Fund Advisers Trust, Fosun International Ltd, Janus Henderson Group PLC, Emerald Advisers Inc. PA, Alliancebernstein L.P., BlackRock Inc. and AXA. View Insider Buying and Selling for Deciphera Pharmaceuticals.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $23.23.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $863.20 million. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.
What is Deciphera Pharmaceuticals' official website?
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
